Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
Status:
Not yet recruiting
Trial end date:
2024-01-10
Target enrollment:
Participant gender:
Summary
The study objective is to determine whether an ICS added for 4 weeks to a baseline treatment
with a Long-Acting Beta-adrenergic Agonist (LABA) and Long-Acting Muscarinic Antagonist
(LAMA) combination improves pulmonary vascular endothelial function as assessed by the
vasodilator response to inhaled albuterol (endothelium-dependent vasodilation) in stable COPD
patients treated with a LABA/LAMA without an ICS for at least one month.